Price
$16.80+87.09%1Y
1M-4.32%1Y+87.09%
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
Above average7/10
Value51
Quality68
Momentum52
Growth48
P/E (TTM)-
Market Cap$17.90B
1Y Return+87.09%
5Y Return+29.17%
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q1 2026Total $3.52B (-9.02%)
●Norvasc grew +21.88% YoY●Dymista -12.85% YoY
SegmentLatestQoQYoY
- Brands$1.07B-13.88%+4.82%
- Generics$951.8M-6.16%+9.16%
- Lipitor$462.0M+16.64%+19.07%
- Norvasc$210.0M+16.86%+21.88%
- Lyrica$120.6M-4.66%+7.10%
- Epi Pen Auto Injectors$101.1M-35.69%+4.55%
- Creon$97.4M+4.62%+18.20%
- Viagra$95.0M-9.70%-3.55%
- Zoloft$72.6M+8.68%+20.60%
- Celebrex$67.1M-8.46%+5.84%
- Yupelri$62.5M-12.46%+7.20%
- Effexor$62.0M-7.74%+4.55%
- Xalabrands$39.2M+1.55%+5.66%
- Dymista$37.3M+10.36%-12.85%
- Xanax$34.8M+1.75%+7.74%
- Amitiza$34.0M-16.67%+2.10%
- Complex GXAnd Biosimilars---
- Influvac---